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ABSTRACT

The Role of Nitric Oxide, Acetylcholine, and Vasoactive Intestinal Peptide
on Skin Blood Flow During In-Vivo Electrical Field Stimulation

Robert S. Thiebaud
Department of Exercise Sciences
Master of Science

The purpose of this study was to characterize a novel technique to study neurogenic
control of cutaneous vasodilation. We monitored skin blood flow (SkBF) during in-vivo
electrical stimulation (e-stim) intended to activate cutaneous nerves and used intradermal
microdialysis to deliver receptor antagonists to characterize their contribution to cutaneous
vasodilation. We examined the role of acetylcholine receptors (RACh), nitric oxide (NO), and
vasoactive intestinal peptide receptors (RVIP) on the cutaneous vasodilation induced by e-stim in
the absence of the sympathetic adrenergic nervous system. Six men and three women
participated in the study. Three intradermal microdialysis probes were placed in the skin of the
dorsal side of their forearm. The adrenergic nervous system was eliminated by delivery of a
cocktail of phentolamine (0.01 mg/ml), propranolol (1 mM), and BIBP-3226 (10 µM). At one
skin site atropine (0.1 mg/ml) was delivered to block RACh. At a second site we blocked nitric
oxide synthase (NOS, 10 mM L-NAME) and RACh. Finally at the third site, we blocked RACh,
NOS, and RVIP (0.47 mg/ml VIP10-28). The SkBF response to 1 minute stages of graded increases
in frequency (0.2, 1, 2, 4, 8, and 32 Hz) at a current of 1.0 ± 0.1 mA was used to generate a
stimulus-response curve before and after drug delivery. At skin site 1 RACh blockade decreased
the area under curve (AUC) by 4% from 614 ± 279 to 591 ± 331 (p>0.05). Nitric oxide synthase
and RACh blockade reduced the vasodilator response to e-stim by 23% from 1036 ± 457 to 801 ±
448 AUC (p>0.05). Combined NOS, RACh, and RVIP blockade reduced the vasodilator response
by 48% from 802 ± 412 to 418 ± 268 AUC (p=0.07). RACh blockade had no effect on the
vasodilator response to e-stim. However, in these preliminary studies both NOS and RVIP
blockade provided some attenuation of the cutaneous vasodilator response associated with estim. Additional studies will focus on these two neurotransmitters as this novel method is
refined. Advantages of e-stim include activating the sympathetic nervous system without
activating local and humoral factors and studying neurotransmitters in an in-vivo setting during
rest, thermal stress, or exercise.
Keywords: Cutaneous circulation, microdialysis, sympathetic, adrenergic, vasodilation,
intradermal, nitric oxide synthase
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Introduction

Adjustments in the cutaneous circulation play a vital role in the regulation of body
temperature during heat stress. The change in cutaneous circulation during heat stress is
controlled by both local and reflex control systems (6). The local response relies on paracrine
release of vasoactive substances from either the vascular endothelium lining (8) and/or other skin
cells, such as keratinocytes (4). In addition, the local response may involve an axon reflex
mediated release of neuropeptides following the activation of a cutaneous nociceptor (16). The
reflex response is mediated by baro- and thermoceptor afferents (8) via activation of the
sympathetic nervous system.
Many of the neurochemicals and paracrine substances involved in these local and reflex
responses have been identified. The sympathetic nervous system controls skin blood flow
primarily by the release of norepinephrine (NE), and its effects on alpha adrenergic receptors
causing contraction of vascular smooth muscle (2, 10). However, sympathetic adrenergic nerves
also release co-transmitters such as neuropeptide Y (19). Active cutaneous vasodilation is
mediated by a sympathetic cholinergic nerve (18). Most scientists believe that the cutaneous
sympathetic vasodilator system releases acetylcholine (ACh) and the co-transmitter, vasoactive
intestinal peptide (VIP), which evokes cutaneous vasodilation (1, 11, 15). However, ACh
receptor (RACh) and VIP receptor (RVIP) blockade during heat stress attenuates, but does not
abolish, cutaneous vasodilation (1). Thus, other neurochemicals must also be involved in
mediating active cutaneous vasodilation. Nitric oxide (NO) is a likely candidate. Local heating
produces NO in the cutaneous interstitial space (12), and blocking NO production during local
heating attenuates the increase in skin blood flow (9). Recently, Kellogg et al. (13) demonstrated
that neuronal nitric oxide synthase (nNOS) is involved the cutaneous dilation associated with
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local heating. While this finding is novel and intriguing, recent work of Stewart, Medow,
Minson and Taneja (20) failed to confirm this observation. It is likely that the complex nature of
the homeostatic response to whole body heating, exercise, or even local skin heating may limit
our ability to differentiate the role of various neurochemicals in the regulation of skin blood flow
(5).
The current study proposes a novel method to investigate neurogenic control of cutaneous
vasodilation. This method involves the placement of two thin stainless steel needles 2 mm deep
into the skin to directly depolarize cutaneous nerves thereby producing the release of their
respective neurochemicals. By combining cutaneous nerve stimulation with local receptor
blockade using intradermal microdialysis and local monitoring of SkBF with laser Doppler
velocemitry, we hope to characterize the contribution of various neurochemicals on skin blood
flow control. Specifically, these series of experiments describe the cutaneous vascular responses
to intradermal electrical stimulation following 1) adrenergic receptor blockade 2) combined
adrenergic receptor and RACh blockade 3) combined adrenergic, RACh blockade, and nonselective inhibition of nitric oxide synthase (NOS) and 4) combined adrenergic, RACh blockade,
NOS inhibition, and RVIP receptor antagonism.
Methods
Nine subjects participated in this study, 6 men and 3 women, with an average age of 23 ±
1 years (1 SEM), height of 173.5 ± 3.6 cm, and weight of 74.6 ± 3.8 kg. All subjects were free
of cardiovascular, renal, or metabolic diseases and abstained from alcohol, caffeine, and exercise
for twelve hours prior to testing. Female subjects were tested during the first seven days of their
menstrual cycle. Written informed consent was obtained before participating in the study which
was approved by the Brigham Young University Institutional Review Board.
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Upon arrival, subjects entered the environmental chamber (room temperature 28.2 ± 0.1
°C) and were fitted with a water-perfused suit that covered the entire body except the head, feet,
hands, and right forearm. The subject then sat upright in a dental chair and was instrumented
with ECG electrodes and a non-invasive automated brachial artery blood pressure cuff (Model
STBP-780, Colin Medical Instruments, Komaki, Japan) on the left arm. The water circulating
through the suit was set at 34 °C throughout the experiment. Next, without anesthesia, three
intradermal microdialysis probes were placed 3-4 cm from the elbow at a depth of 1-2 mm in the
skin of the dorsal aspect of the right forearm using a 27 gauge needle as a guide cannula.
Approximately 4-5 cm separated each probe and sterile saline was perfused through the probes at
10 µl/min for the next 120 minutes to allow the skin to recover from the insertion trauma.
Specially made Plexiglas probe holders were placed directly over the path of the hollow
fiber portion of the microdialysis probe using double-stick tape. A laser Doppler flow probe
placed in the middle guide tube (directly over the microdialysis probe) monitored changes in skin
blood flow (SkBF) using a VP12 flow probe connected to a moorLAB laser Doppler system
(time constant set at 1.0 sec, sampling rate set at 20 Hz) (Moor Instruments, Devon, England) .
On either side of the laser Doppler probe holder were two guide tubes where the stimulating
electrodes (stainless steel acupuncture needles) were inserted 2 mm deep into the skin with a tip
separation of < 4 mm. The stimulating electrodes were then connected to a constant current
stimulator (Model DS7AH, Digitimer Ltd., West Garden City, England) whose frequency was
driven by a Grass S88 stimulator (Model Grass S88 Stimulator, Grass Instrument Co., Quincy,
MA). A thermocouple was placed between the Plexiglas probe holder and skin to measure local
skin temperature.
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The amplitude of the electrical current that activated the perivascular nerves surrounding
the cutaneous blood vessels and elicited a vasomotor response was determined individually for
each skin site. Initially, single pulses of the electrical stimulus were sent to the skin starting at
0.5 mA. The stimulus, when detected, typically felt like a “tapping” sensation on the skin. If the
subject could not detect the stimulus pulse, the current level was increased by 0.1 mA until the
stimulus was detected. If the stimulus was initially felt at a stimulus strength of 0.5 mA, the
current was decreased 0.1 mA until the stimulus was not detected. A current level 0.1 mA above
where the stimulus was not detected was set as the initial current stimulus. At this predetermined current level, the stimulus frequency was then set at 8 Hz and the current increased
0.2 mA every 20 seconds until a significant change (increase or decrease) in SkBF occurred. A
significant change in SkBF was defined as ± 0.5-0.7 V change in the voltage output from the
laser Doppler system. After a five minute recovery period, the selected amplitude was retested
by applying a minute stimulus at a frequency of 8 Hz to confirm that a significant change in
SkBF occurred. If the response was not confirmed then the current amplitude was increased 0.2
mA and retested five minutes later. This method was used for all three sites to identify the
current amplitude to be used at each skin site.
Based upon the current intensity that elicited a significant change in SkBF, we produced
stimulus-response curves for each skin site by plotting SkBF as a function of the stimulus
frequency. To generate the stimulus response curve we used a graded stepwise increase in
stimulus frequency (0.2, 1, 2, 4, 8, and 32 Hz) with each step lasting 1 minute (Figure 1). After
the last stimulus at each site, the subject rated the pain of the stimulus on a 11-point modified
Borg scale from 6-16 with 6 indicating no pain at all and 16 indicating unbearably painful (14).
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Experimental Protocol
The experimental protocol is outlined in Figure 2. Sixty minutes following the
determination of the electrical current amplitude that elicited a significant change in SkBF, a
cold challenge test (CCT) was administered to verify sympathetic mediated cutaneous
vasoconstriction. The water circulating through the water-perfused suit was rapidly switched to
a cold water bath (4 °C), and the subject was cooled for 3 minutes. SkBF was recorded
continuously and blood pressure was recorded once every minute. Fifteen minutes after the end
of the CCT the first dose response curve was performed. Blood pressure was measured every
minute during the CCT and every seven minutes during remaining portions of the experimental
protocol.
After performing the initial stimulus response curve, each skin site was treated with a
cocktail of blocking agents. Every drug cocktail contained a basic mixture of adrenergic
receptor blockers phentolamine (0.01 mg/ml) and propranolol (1 mM) and the neuropeptide Y
receptor antagonist BIBP-3622 (10 µM). In addition to the adrenergic blocking combination,
one drug cocktail contained atropine (0.1 mg/ml ), one contained atropine (0.1 mg/ml) and nitroL-arginine methyl ester (10 mM L-NAME), and one contained atropine (0.1 mg/ml), L-NAME
(10 mM) and VIP10-28 (0.47 mg/ml). Each cocktail was delivered for 30 minutes at 3 µl/min
using a Harvard infusion pump (Model PHD 2000, Harvard Apparatus, Holliston, MA). The
drug cocktails were randomly assigned to different skin sites. Following the 30 minute perfusion
period a second set of stimulus-response curves at each skin site was performed. Fifteen minutes
after the last stimulus-response curve, a second CCT was performed to verify adrenergic
blockade. Finally, 28 mM sodium nitroprusside (SNP) was perfused at 5 µl/min for 30 minutes
to determine the maximum skin blood flow at each site.
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Data Analysis
SkBF and local skin temperature were recorded continuously at 400 Hz using a
PowerLab 16S (ADInstruments Pty Ltd., Castel Hill, Australia). The SkBF and skin temperature
data were then averaged every 5 seconds for analysis. Cutaneous vasomotor response to the
electrical stimulus is described by changes in cutaneous vascular conductance (CVC).
Cutaneous vascular conductance was calculated by dividing the voltage output of the laser
Doppler flow probe by the average mean arterial blood pressure. Cutaneous vascular
conductance was expressed as a percent of maximal CVC obtained during administration of 28
mM SNP. During each graded stepwise increase in stimulus frequency the CVC response was
characterized by the area under the CVC–time response curve (AUC) for each minute stimulus
period. In the calculation of AUC, CVC was expressed as a percent of the CVC measured just
prior to electrical stimulation (Figure 1).
The data were analyzed using a general linear model repeated measures ANOVA using
SAS (SAS 9.2) with post hoc comparisons between groups performed using Tukey’s MSD test.
The stimulus response curves were also analyzed to determine the EC50 threshold and saturation
level using non-linear sigmoidal dose-response curve fit (Prism, GraphPad Software Inc, San
Diego, CA).
Results
Preliminary studies
Electrical stimulation of the skin produced two basic vascular responses: constriction or
dilation (Figure 1). In preliminary experiments we verified that we were activating sympathetic
nerves in the skin by using a biological assay. In this case we monitored local sweat production
during similar stimulus conditions. Figure 3 illustrates the ability of our stimulus parameters to
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activate sweating in a dose dependent manner. This sweating response is abolished by atropine
and thus represents the effects of the stimulus to depolarize sympathetic sudomotor nerves and
cause the release of ACh leading to sweat production.
Additionally, preliminary studies demonstrated that use of our graded staircase stimulus
pattern did not bias our results. In these preliminary studies we compared the impact of
performing each one minute frequency stimulation in random order spaced five minutes apart
versus our staircase approach. The data shown in Figure 4 indicates identical stimulus-response
curves for both experimental approaches. As such, we used the shorter staircase stimulus to
evaluate the CVC response.
Figure 5 shows the time course of SkBF during the cold challenge test before and after
perfusion of our adrenergic blocking drug cocktail. CVC levels dropped by 16 ± 3 % (p<0.05)
during the cold challenge prior to blockade and decreased by 9 ± 2 % after adrenergic blockade.
After review of each skin site response to CCT, it appeared that less than 50% of the sites
demonstrated adequate adrenergic blockade: Atropine site, n=3; Atropine and L-NAME site,
n=4; Atropine, L-NAME, and VIP10-28 site, n=6.
Figure 6 describes the average area under the CVC-time curve (AUC) for each stimulus
frequency before (saline) and after each blocking cocktail. Before infusion of atropine, the
highest stimulation frequency of 32 Hz caused AUC to increase to an average of 614 ± 279.
After infusion of atropine, AUC increased to an average of 591 ± 331. Infusion of atropine and
L-NAME appeared to decrease dilation, compared to saline, by 23% from 1036 ± 457 to 801 ±
448 AUC (p>0.05). Infusion of atropine, L-NAME, and VIP10-28 decreased dilation by 48%
from 801 ± 412 to 418 ± 268 AUC (p>0.05). The stimulus-response curves for the three saline
sites were similar and therefore pooled together to provide an average response (Figure 7). The
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AUC for CVC increased significantly from 0.2 Hz at 2, 4, 8, and 32 Hz in the saline and atropine
sites indicating dilation. In contrast, the AUC for CVC did not increase significantly with
varying frequencies in the atropine & L-NAME or atropine, L-NAME, & VIP10-28 sites indicating
no significant dilation. Calculated EC50 levels from the stimulus-response curves are shown in
Figure 8. The EC50 averaged 3.1 ± 1.1 Hz during saline infusion and was unchanged during
atropine infusion averaging 3.2 ± 1.2 Hz. Infusion of atropine and L-NAME causes a small
increment in the EC50 to 5.6 ± 1.2 Hz while infusion of atropine, L-NAME, and VIP10-28
increased the EC50 to 6.1 ± 1.5 Hz (p=0.08).
Table 1 lists the average skin temperature, pain, and current amplitude for each of the
three skin sites. There were no differences in these parameters for any skin site. Overall, the
average of all three sites for skin temperature, rating of perceived pain, and current amplitude
was 32.9 ± 0.2 °C, 7.8 ± 0.6 (on a 6-16 point scale), and 1.0 ± 0.1 mA, respectively.
Discussion
We developed a method of in-vivo electrical stimulation (e-stim) in an attempt to provide
insight into the neural control of SkBF. This preliminary study provides compelling evidence
that intradermal e-stim is a viable method to evaluate neurovascular control of SkBF. The first
novel observation was that blockade of RACh with atropine had no impact on the magnitude of
cutaneous vasodilation associated with e-stim. Combined blockade of RACh and NOS activity
reduced dilation by 23% compared to no blockade. Although this difference was not statistically
significant it suggests a small contribution of NO to this dilator response. This may be
physiologically significant in the fact that NO’s ability to reduce SkBF by 23% may have some
effect in producing sufficient dilation to release heat from the body during thermal stress or
exercise.
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Finally, RVIP inhibition produced a greater attenuation (about 48%) of the CVC response to estim. Although the attenuated response was not statistically significant, the reduction of dilator
response with RVIP blockade is of interest. A decrease in almost 50% of CVC demonstrates that
nearly half of the vasodilation occurring in skin may be contributable to ACh, NO, and VIP.
Furthermore, VIP blockade nearly doubled the decrease in SkBF compared to NOS blockade.
Physiologically, VIP may play a vital role in vasodilation. Increasing the power of the study by
adding more subjects could help to identify a greater role for NO or RVIP in this e-stim mediated
dilation.
When performing our preliminary tests, we did verify that both sympathetic adrenergic and
cholinergic nerves were activated by the e-stim. Blocking the release of sympathetic adrenergic
neurotransmitters with bretylium tosylate completely eliminated the vasoconstrictor response; in
fact, the SKBF response was transformed into dilation (Figure 10). Also, the e-stim protocol
depolarized sympathetic sudomotor nerves causing the sweat rate to increase (Figure 3).
Another interesting observation was the large variability in SkBF response to e-stim at each
site. One possible explanation for this observation is the great variability in C-nociceptor fiber
innervation density of the skin. Our previous observations of activation of the sympathetic
nervous system with e-stim suggest that our stimulus parameters were appropriate to activate
sympathetic C-nociceptor fibers in the skin. Schmidt et al. (17) discovered many different sizes
and shapes of mechanically activated C-nociceptor innervation territories. Activation of these Cnociceptor fibers during e-stim could potentially release vasodilator substances. During this
study involving e-stim, sites expressed either an increase or decrease in SkBF with e-stim. Sites
that expressed an increase in SkBF may have contained more of these C-nociceptor fibers than
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sites that expressed a decrease in SkBF. The great variation in size and shape of C-nociceptor
innervation territories could explain why we had varying results.
In-vivo electrical field stimulation may increase the release of VIP, a cutaneous
vasodilator. Recently, Kellogg et al. (7) demonstrated that VIP was involved in cutaneous
vasodilation. Bennett et al. (1) also found similar findings. Bennett et al. (1) used intradermal
microdialysis probes to infuse VIP and VIP10-28, a RVIP antagonist, into human skin. During
heating, the site with VIP10-28 alone caused blood flow to increase to around 27% of maximum
blood flow. With VIP10-28 and atropine, blood flow levels increased to around 20% maximum
blood flow. The blood flow in the control site increased to 35% of maximum blood flow (1).
The findings of Bennett et al. provide evidence that VIP contributes to active cutaneous
vasodilation associated with heat stress. Interestingly, Bennett et al. noted that when RVIP
blockade was combined with RACh blockade that cutaneous vasodilation was reduced from 35%
max CVC (RACh blockade) to 20% max CVC (RVIP blockade and RACh blockade). In the present
study, we saw a 48% decrease in AUC when we delivered VIP10-28 supporting the work of
Bennett et al., but we saw no added impact when combined with RACh blockade. The
interpretation of our results is limited due to lack of statistical significance.
Because Bennett et al. (1) did not observe a complete elimination of dilation with VIP and
atropine, we hypothesized that NO may have enabled the cutaneous vasodilation during heating.
The importance of NO in increasing blood flow has clearly been demonstrated in previous
studies. Kellogg et al. (9) inserted intradermal microdialysis probes in two sites in the forearm of
subjects and perfused one site with nitro-L-arginine methyl ester (L-NAME) which is a
nonselective blocker of nitric oxide synthase (NOS), and the other site was perfused with Ringer
solution. In the untreated site when local skin temperature was raised to 38-38.5 °C, blood flow
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rose to 44% of maximum blood flow and in the L-NAME site blood flow rose to 30% maximum
blood flow (9). By blocking NOS, blood flow did not increase similarly to blood flow in skin
with unblocked NOS. Nitric oxide production is clearly needed during local heating to induce
increases in skin blood flow.
Recent evidence suggests that neuronal nitric oxide synthase (nNOS) produces the NO that
causes reflex vasodilation during whole-body heating. Kellogg et al. (13) used 7-nitroindazole
(7-IN), a selective antagonist of nNOS, to study nNOS involvement in thermoregulatory reflex
vasodilation. One site was infused with 5% DMSO and Ringer solution, while the other site was
infused with 2 mM 7-NI with 5% DMSO. In one protocol subjects core temperature was
elevated by 1°C using a whole-body suit with the forearm being uncovered. In another protocol
subject’s forearms were locally heated to 41.5 °C. In the whole-body heating protocol, 7-NI
significantly decreased skin blood flow when compared to the control site by 15%. However, in
the protocol with local skin warming, no significant difference was seen between the 7-NI site
and control site (13). Kellogg et al.’s findings show that nNOS is involved in the
thermoregulatory reflex response during whole-body heating due to the attenuation seen with the
blockade of nNOS.
When examining the role of NOS during e-stim we noted a small (23%) reduction in
cutaneous vasodilation. The lack of significance might indicate that NO is not typically released
in response to depolarization of nerves. Because e-stim did produce a small change in dilation
with blockade of NO, nNOS may contribute to a small portion of cutaneous vasodilation as
proposed by Kellogg et al. (13), but this has yet to be confirmed (20). Clearly, further
refinement of our e-stim protocol is required to address relatively small effects of NOS on our
cutaneous vasodilator response to e-stim. Our results also indicate the lack of complete blockade
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of vasodilation during e-stim following infusion of ACh, NOS, and VIP antagonists. The
continued presence of vasodilation during e-stim may be due to some other substance or
substances. Possible vasodilator substances released from cells could have been prostanoids or
histamine.
E-stim may have activated nociceptor fibers which release neuropeptides such as calcitonin
gene-related peptide (CGRP) and substance P via an axon reflex. One way to indicate if these
nociceptor fibers were activated is to determine the perceived pain felt by the subject during the
stimulus. Subjects rated pain on a scale of 6-16 with 6 indicating no pain at all and 16 indicating
unbearable pain. The average pain rating was between 7-8 for each site. Despite the low pain
ratings, the nociceptors could have still been activated. In preliminary testing there was no
significant axon reflex increase in SkBF during e-stim with the current levels or frequencies
used. As such, we have no evidence that our stimulus parameters activated cutaneous
nociceptors thereby eliciting an axon reflex. Furthermore, 5-10 minutes after e-stim SkBF
returned to baseline levels (Figure 9). Generally, the activation of nociceptor fibers cause the
release of neuropeptides such as CGRP which produce a large and prolonged vasodilation (3).
These observations indicate that CGRP and substance P were most likely not important
factors causing the dilation seen during ACh, VIP, and NOS blockade. In preliminary studies the
desensitization of nociceptors with chronic capsaicin application had little impact on the SkBF
response to e-stim (Figure 11). In addition, blockade of the CGRP receptor with the CGRP (837) had little impact on the SkBF response to e-stim (Figure 11). However, these substances
were not blocked in the current study and future studies with e-stim are required to verify this
assumption.
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Several key limitations existed in this study. Figure 3 shows poor adrenergic blockade.
Following the administration of adrenergic blocking agents, SkBF decreased significantly from
baseline levels during the cold challenge test indicating a poor adrenergic blockade. In addition,
we were not confident that the CCT provided an adequate evaluation of adrenergic blockade. If
the SkBF levels were too low before the CCT, then a false positive result would be observed
indicating sufficient adrenergic blockade when in fact sufficient adrenergic blockade was not
present. Our results in Figure 3 could be due to an insufficient concentration of the adrenergic
drug cocktail. In follow-up work with higher concentrations of phentolamine, we noted a much
more pronounced attenuation of the CCT. We recommend that future studies focus first on
determining a strong enough concentration of phentolamine to produce an adequate adrenergic
blockade. Second, low resting SkBF levels appeared to limit the effectiveness of the CCT
response. When resting SkBF levels were low we could identify very little change in SkBF
during the CCT regardless of whether adrenergic blockade was adequate. More recently, we
have used the delivery of 6.3 x 10-6 M norepinephrine to the skin to evaluate adrenergic
blockade. We recommend that future studies use this technique to verify adrenergic blockade.
In summary, in the absence of a functioning sympathetic adrenergic system, intradermal
e-stim produced a graded dilation proportional to the frequency of a non-painful stimulus.
Blocking of RACh by itself did not blunt the dilatory response seen by e-stim. In contrast, we
noted sufficient attenuation of the dilator response (>23%) following NOS or RVIP blockade to
suggest that a refinement of this technique could identify the contribution of specific neurogenic
vasodilator substances to active cutaneous neurogenic vasodilation. These data indicate the
possible contribution of NOS and/or VIP in regulating vasodilation in the cutaneous circulation.
Future studies using e-stim to identify specific neurogenic vasodilator substances may need a
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greater concentration of blocking agents or other receptor systems may need to be removed such
as nociceptors (with capsaicin) or prostanoids (with COX inhibitors). Several advantages of this
technique will arise as this method is refined. One advantage of using in-vivo electrical field
stimulation is the activation of the sympathetic nervous system without interacting with various
humoral factors that are released during either exercise or whole body heating. Another potential
advantage of this technique is the ability to activate the cutaneous sympathetic nerves in human
skin under a variety of conditions to evaluate its interaction with other homeostatic control
mechanisms.
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Figure Legends
Figure 1. Representative tracings of the cutaneous vascular conductance (CVC) responses to
intradermal stimulation (top) and the dose-response curves generated from these data (bottom).

Figure 2. Timeline of Experimental Protocol. Each skin site was perfused with a cocktail of
adrenergic blocking agents containing 0.01 mg/ml phentolamine, 1 mM propranolol, and 10 µM
BIBB-36220. Each of the three solution (C through E) represents the combination of the
adrenergic blocking cocktail and a blocking agent for a suspected dilator substance: Sol. C = 0.1
mg/ml atropine; Sol. D = 0.1 mg/ml atropine and 10 mM nitro-L-arginine methyl ester (LNAME); and Sol. E = 0.1 mg/ml atropine, 10 mM (L-NAME), and 0.46 mg/ml Vasoactive
Intestinal Peptide (VIP10-28). SNP = 28 mM sodium nitroprusside, EFS = intradermal electrical
field stimulation, CCT = cold challenge test.

Figure 3. Impact of graded levels of intradermal stimulation on local sweat rate.

Figure 4. Comparison of dose-response curves generated by a random application of 1 minute
intradermal stimulation spaced 5 minutes apart and a graded staircase stimulation from 0.1 to 32
Hz at identical current intensity. Values represent the mean and SE of 4 subjects.
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Figure 5. Change in cutaneous vascular conductance (CVC) expressed as a % of baseline
during the three minute cold challenge test with and without the presence of the adrenergic
blocking cocktail of 0.1 mg/ml phentolamine, 1 mM propranolol, and 10 µM BIBB-36220.
Values represent the mean ± 1 SEM for n=27 skin sites. * p<0.05 Adrenergic Blockade different
from Saline. † p<0.05 different from time = 0.

Figure 6. Staircase response curves before and after solution treatments. Area under the skin
blood flow–time response curve (AUC) where skin blood flow is expressed as a percent of
resting blood flow prior to electrical stimulation. The dose response curve therefore reflects the
plot of stimulus frequency versus the AUC for skin blood flow.

Figure 7. Frequency effect on SkBF during in-vivo electrical field stimulation. Area under the
SkBF–time response curve (AUC) where SkBF is expressed as a percent of resting blood flow
prior to electrical stimulation. * p<0.05 different from 0.2 Hz.

Figure 8. Effects of vasodilator antagonists on the EC50 stimulus frequency for the area under
the CVC–time response curve (AUC) where CVC is expressed as a percent of resting CVC just
prior to electrical stimulation. EC50 represents the estimated frequency to produce 50% of the
peak dilation at 32 Hz.

Figure 9. Example of SkBF recovery in one site from in-vivo electrical field stimulation. SkBF
returns back to baseline levels 5-10 minutes after stimulus.
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Figure 10. Effect of 100 mM bretylium tosylate on the skin blood flow response to e-stim. Area
under the SkBF–time response curve (AUC) where SkBF is expressed as a percent of resting
blood flow prior to electrical stimulation. The dose response curve therefore reflects the plot of
stimulus frequency versus the AUC for skin blood flow.

Figure 11. The effect of chronic topical application of capsaicin or microdialysis delivered
calcitonin gene-related peptide fragment CGRP (8-37) on SkBF during e-stim. Area under the
SkBF–time response curve (AUC) where SkBF is expressed as a percent of resting blood flow
prior to electrical stimulation.
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Table 1
Mean averages of skin temperature, pain levels, and current amplitudes. Values are mean ±
SEM for 9 subjects. Site location as referenced from the elbow.
Skin Site
Distal Site
Middle Site
Proximal Site

Skin Temperature, °C
32.8 ± 0.3
33.5 ± 0.2
32.5 ± 0.2

Stimulus Current, mA
1.0 ± 0.1
1.1 ± 0.2
0.9 ± 0.1

Pain Rating (6-16)
7.6 ± 0.5
7.7 ± 0.6
8.1 ± 0.6
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Chapter 1
Introduction

Body temperature regulation during thermal stress and exercise allows the body to
maintain homeostasis. Adjustments in the cutaneous circulation play a vital role in this
regulation. The change in cutaneous circulation during exercise and/or thermal stress is
controlled by both local and reflex systems (17). The local response relies on circulating pressor
hormones and chemicals released from the vascular endothelium lining and the skin
keratinocytes (18). The reflex response is controlled by cardiovascular, thermal, and nociceptor
afferents (18). These afferent signals control the skin blood flow through activation of the
sympathetic nervous system.
The sympathetic nervous system controls skin blood flow through sympathetic adrenergic
and cholinergic nerves. The sympathetic adrenergic nerves release norepinephrine.
Norepinephrine is the predominant neurochemical producing vasoconstriction in the blood
vessels (4, 20). However, sympathetic-mediated vasodilation (active cutaneous vasodilation) is
mediated by an unknown neurochemical. Most scientists believe that the cutaneous sympathetic
vasodilator system releases acetylcholine (ACh) and a cotransmitter (vasoactive intestinal
peptide, VIP) to evoke vasodilation (3, 22, 28). However, when ACh and VIP receptors are
blocked during heat stress, a decrease in skin blood flow occurs, but the original vasodilation is
not completely abolished (3). Thus, another neurochemical must be involved in mediating active
cutaneous vasodilation. Nitric oxide (NO) is a likely candidate. NO is found readily in the
cutaneous interstitial space during heating (23), and when NO is blocked during heating, the
increase in skin blood flow is attenuated (19).
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One way to examine the effects of ACh, VIP, and NO on control of skin blood flow
during thermal stress is through the use of microdialysis probes and laser Doppler probes.
Infusing antagonists into the dermal space of the skin, via microdialysis probes, allows the
examination of local skin blood flow response to heating without systemic effects. Currently, the
ability to differentiate the role of various neurochemicals on the skin blood flow response to
thermal stress is limited by the numerous systemic effects imposed upon the body by either the
thermal stress (high ambient temperature) or exercise used to induce the thermal stress (12).
In order to avoid the systemic effects produced during thermal stress and exercise, we
have developed a novel method to investigate neurogenic control of skin blood flow by directly
stimulating perivascular nerves. This method involves in-vivo electrical field stimulation. Invivo electrical field stimulation uses electrodes (thin stainless steel acupuncture needles) placed 2
mm deep into the skin. A constant current applied to the electrodes causes depolarization of all
perivascular nerves thereby producing the release of their respective neurochemicals. By
combining intradermal electrical stimulation with measurements of the skin blood flow and
intradermal microdialysis, the specific effect of each known neurochemical on skin blood flow
should be differentiated.
Problem Statement
Using in-vivo electrical field stimulation and eliminating the action of norepinephrine
released from sympathetic adrenergic perivascular nerves (vasoconstriction) with adrenergic
blocking agents, we should be able to identify the contribution of ACh, NO, and VIP to
vasodilation in the skin. Thus, the purpose of this study is to specifically quantify the influence
of ACh, NO, and VIP released from perivascular nerves on skin blood flow in the forearm.
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Hypotheses
First, blocking ACh and NO will reduce the increase in skin blood flow during electrical
stimulation greater than only blocking ACh.
Second, blocking ACh, NO, and VIP will reduce the increase in skin blood flow during
electrical field stimulation greater than only blocking ACh.
Third, blocking ACh, NO, and VIP will reduce the increase in skin blood flow during
electrical field stimulation greater than blocking ACh and NO.
Null Hypotheses
First, skin blood flow will not be significantly different when blocking ACh and NO
during electrical stimulation when compared to only blocking ACh.
Second, skin blood flow will not be significantly different when blocking ACh, NO, and
VIP during electrical stimulation when compared to only blocking ACh.
Third, skin blood flow will not be significantly different when blocking ACh, NO, and
VIP during electrical stimulation when compared to blocking ACh and NO.
Assumptions
Nociceptor nerves are not being activated due to low levels of pain exerted by the
electrical field stimulation as determined by the perceived pain scale.
Delimitations
The findings will only be applicable to blood flow in the forearms.
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Limitations
If nociceptor nerves are activated by the electrical stimulation, an axon reflex will occur
away from the electrical stimulation site causing an increase in skin blood flow. However,
because of limited laser Doppler probes, we will only measure skin blood flow directly over
electrical stimulation sites.
Significance of the Study
The regulation of cutaneous circulation is a vital component in keeping core body
temperature at viable levels. Understanding how skin blood flow is regulated will help
determine ways to effectively treat individuals who may have impaired cutaneous circulation.
No one has used the novel method of in-vivo electrical field stimulation to study skin blood flow.
The results of this study will increase insight into the involvement of different neurochemicals
released from the perivascular nerves on cutaneous circulation.
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Chapter 2
Review of Literature

Cutaneous circulation is extremely important in regulating body temperature during
exercise and during exposure to cold and heat. The ability of the body to respond rapidly to
different thermal stimuli depends on a variety of signaling systems that include both reflex and
local responses. Reflex neural control involves sensory information from thermal,
cardiovascular, and nociceptor afferents (18). In particular to skin blood flow, the neural control
involves perivascular nerves that surround the skin blood vessels which include adrenergic,
cholinergic, sensory afferent, and nitrodergic neurons (18). Local control involves the action of
circulating pressor hormones (angiotensin II, arginine vasopressin) and paracrine release of
substances such as nitric oxide, prostaglandins, and histamine from the blood vessel endothelium
or keratocytes (18). This review will focus on the role of perivascular nerves in the reflex
control of skin blood flow.
Thermoregulatory Control of Skin Blood Flow
Skin blood flow is mainly affected by thermal stress. One of the original studies
examining local thermal stress on forearm blood flow was done by Barcroft and Edholm (2). In
their study, they immersed subject’s forearms in water baths at different temperatures and found
that temperatures above 35 °C caused vasodilation while forearm blood flow was significantly
reduced at temperatures below 35 °C (2). Taylor, Johnson, O’Leary, and Park (35) found that
when the skin was heated to 42 °C, forearm blood flow rose substantially. They discovered that
maximal forearm skin blood flow averaged 21 ml•100 ml-1 •min-1 which when extrapolated to
approximate whole-body skin blood flow equaled about 7.6 L•min-1 (35). These early studies
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demonstrate the large increase in local skin blood flow that occurs during heat stress. In these
studies, blood flow was measured in the arm that was heated or cooled. Because of this, the
responses reflect a combination of local and reflex responses to temperature. Wenger,
Stephenson, and Durkin (37) performed similar experiments following brachial plexus blockade.
After nerve block they saw similar increases in forearm skin blood flow with or without nerve
block. As such, most of the increase in forearm skin blood flow during local heating could be
attributed to a local response. Despite the fact that these responses were mainly mediated by
local factors, they demonstrated the significant change that occurs to skin blood flow during
thermal stress.
Reflex thermoregulatory responses in the skin are derived from afferent thermal
information sent to the hypothalamus where it is integrated and an appropriate effector organ
response is generated (i.e., dilation or constriction). One efferent pathway used to control skin
blood flow through the activation of thermal reflexes is the sympathetic nervous system. The
sympathetic nervous system’s involvement in regulating blood flow during heat and cold stress
is extremely important. The efferent motor output of the sympathetic nervous system is
composed of both sympathetic noradrenergic vasoconstrictor neurons and sympathetic
cholinergic neurons. The sympathetic noradrenergic vasoconstrictor neurons innervate both
glabrous skin (nonhairy skin) (10) and nonglabrous skin (hairy skin) (18) in humans. The
sympathetic cholinergic neurons innervate nonglabrous skin, but they do not play a significant
role in glabrous skin blood flow (10, 14, 15).
The sympathetic noradrenergic system controls reflex vasoconstriction in skin blood
vessels in response to a variety of systems including thermal and cardiovascular reflexes. Early
studies identified the involvement of sympathetic noradrenergic neurons through
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sympathectomies of various neurons. To examine the vasoconstrictor activity in the forearm,
Warren, Walter, Romano, and Stead (36) blocked the sympathetic ganglia of the upper right
extremities by a paravertebral injection of novacaine. The nerve block caused a significant
increase in blood flow in the right forearm compared to blood flow before the sympathectomy
(36). Due to the increased blood flow with nerve blockade, it was concluded that a sympathetic
vasoconstrictor system must have been active when the nerves were not blocked.
To examine the pharmacological control of blood vessels during activation of the
sympathetic noradrenergic system, different adrenergic-receptor blocking agents have been used.
One particular blocking agent that is effective in blocking the sympathetic noradrenergic system
is bretylium tosylate. Blair et al., (4) studied the response of forearm blood flow after infusing
bretylium during cold stress, heat stress, valsalva manoeuvre, and emotional stress. When
bretylium was infused during cold stress and the valsalva manoeuvre, blood flow did not
decrease as seen in the control arm. When bretylium was infused during heat stress and
emotional stress, blood flow increased similarly in the control and bretylium arms (4). Because
no vasoconstriction occurred during cold stress and the valsalva manoeuvre it was concluded that
bretylium treatment blocked sympathetic noradrenergic vasoconstrictor activity. Furthermore,
because the vasodilation occurred during heating and emotional stress with bretylium, the
vasodilator system was not affected by bretylium. Bretylium effectively blocks the sympathetic
noradrenergic system and not the sympathetic cholinergic system.
Skin blood flow in the forearm is also controlled by an active sympathetic vasodilator
system. Johnson and Proppe (17) described active as meaning that “an increase in SkBF arises,
either directly or indirectly, from increased efferent nerve activity.” Early studies indicated that
an increase in skin blood flow in the forearm was controlled by a sympathetic vasodilator
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system. Barcroft, Bonnar, and Edholm (1) did unilateral upper limb sympathectomies on
subjects. After the sympathectomies, they placed the subject’s feet in 44-45 °C water and put
blankets on them for 50 minutes. No significant increase in blood flow was seen in the
sympathectomized forearm after heating, but a significant increase in blood flow was seen in the
normal forearm (1). These results show that a sympathetic vasodilator system controls blood
flow during heat stress.
Edholm, Fox, and Macpherson (9) confirmed the involvement of a sympathetic
vasodilator. They blocked the cutaneous nerves with a 2% solution of lignocaine at the tip of the
olecranon. Control subjects received injections of saline in this area. When the body core
temperature was elevated to 38 °C, forearm blood flow in the anesthetized forearm did not
increase. However, forearm blood flow in the normal arm injected with saline increased
significantly (9). Furthermore, when lignocaine was injected during heating, blood flow
decreased (9). Because blocking cutaneous nerves caused a decrease in forearm blood flow
during heating, an increase in blood flow is due to some type of sympathetic nerve activity.
In order to study the active sympathetic vasodilator system without the involvement of
the sympathetic noradrenergic system, bretylium tosylate has been used. As mentioned earlier,
Blair et al. (4) determined that bretylium blocked the vasoconstrictor sympathetic nerves but did
not block the sympathetic vasodilation nerves. However, his study used venous
plethysmography to evaluate blood flow, and they infused bretylium throughout the body which
may have caused systemic effects.
Kellogg et al. (20) avoided systemic problems by delivering bretylium tosylate to the skin
through intradermal microdialysis probes. They found that with bretylium tosylate delivery to
the skin, no cutaneous vasoconstriction occurred during cold stress. However, during heat stress
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the bretylium tosylate failed to abolish the rise in blood flow (20). By effectively infusing
bretylium in one site without affecting the active vasodilator system, an effective way for
studying the active vasodilator by itself has been found without any possible systemic
confounders.
Evidence for Sweating and Vasodilation
One possible theory that may explain how vasodilation occurs is the link between
sweating and vasodilation. Sweat glands are innervated by sympathetic cholinergic sudomotor
nerves. When these nerves activate sweat glands, a vasodilator substance called bradykinin is
also released. Fox and Hilton (11) examined the relationship between bradykinin formation in
humans and vasodilation. When the body was heated, subcutaneous bradykinin levels were five
times higher compared to resting levels. The increase in bradykinin levels correlated with the
onset of vasodilation. Sweating occurred when the bradykinin activity reached its peak (11).
Because vasodilation corresponded with increased levels of bradykinin, bradykinin was thought
to be a factor in skin vasodilation.
However, more recent evidence suggests that bradykinin blockade does not alter active
cutaneous vasodilation. Kellogg, Liu, McAllister, Friel, and Pergola (21) used 40 μM of the
bradykinin B2-receptor antagonist HOE-140 to see if bradykinin caused vasodilation in heated
subjects. Skin temperature rose 1°C and vasodilation occurred both in the untreated sites and
HOE-140 treated sites. No significant difference in vasodilation between the two sites happened.
The authors concluded that bradykinin did not play a role in cutaneous vasodilation with heat
stress because bradykinin blockade did not decrease vasodilation (21).
Other evidence supporting the idea that sweat glands may play a role in vasodilation in the skin
is seen in patients without sweat glands. Brenglemann, Freund, Rowell, Olerud, and Kraning (5)
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studied vasodilation in the forearm of subjects with hereditary anhidrotic ectodermal dysplasia
(AED). Subjects with AED do not have functioning sweat glands. In their experiment, subjects
were clothed in water-perfused suits, and their oral temperature was increased 1.4-1.7 °C above
resting body core temperature. Measuring blood flow with venous occlusion plethysmography,
they did see evidence of sweating and did not find a significant increase in blood flow (5). These
findings indicate that sweat glands play some role in active vasodilation in the skin.
Evidence against Sweating and Vasodilation
Despite the evidence supporting a link between sweating and vasodilation, evidence also
exists that does not support it. One idea that contradicts the role of sweating and vasodilation is
the different timing associated with sweating and vasodilation. If sweating was essential for
vasodilation then the onset of sweating should always precede the onset of cutaneous
vasodilation. When examining vasodilation and sweating, Johnson and Park (16) did not see a
similar shift in sweat rate and vasodilation during exercise and rest. Subjects were heated with
water-perfused suits to 38-38.5 °C for 60-75 minutes in supine and upright positions. Bicycle
exercise in the upright and supine positions was done for 20-30 minutes. The threshold
esophageal temperature (body core temperature) at which cutaneous vasodilation occurred was
delayed during exercise, but the onset of sweating was unchanged (16). Because sweat rate did
not change similarly to forearm skin blood flow during exercise, sweating may not be the most
important factor contributing to vasodilation in the skin.
Evidence against sweating and vasodilation is obtained when sweating is blocked with
atropine, but cutaneous vasodilation still occurs. Kolka, Stephenson, Allan, and Rock (27)
examined the effects of atropine on vasodilation. Subjects started in a cool environment of 22
°C. Two separate trials were done on individuals such that one day they received an atropine

44
treatment and another day they received a saline treatment. Subjects exercised for 30 minutes at

 O2 peak. During exercise, forearm sweating decreased significantly with
55% of their V
atropine treatment compared to control trials. However, despite the decrease in sweating,
forearm skin blood flow increased to a similar degree in control and atropine treated subjects
(27). Because forearm blood flow increased when blocking sweat gland output, sweating may
not play as significant a role in skin vasodilation as earlier proposed.
Cotransmitter Vasodilator System
One possible explanation of the increased blood flow despite the blocking of ACh’s
action on sweat glands may be related to the release of a cotransmitter from sympathetic
cholinergic nerves.

Kellogg et al. (22) determined that active cutaneous vasodilation is caused

by the release of neurotransmitters from a cholinergic nerve in humans. To determine this, an
area of 0.6 cm2 on the nonglabrous skin of the forearm was injected with 5 U of botulinum toxin.
Botulinum toxin acts presynaptically on the cholinergic nerves and blocks the release of ACh
and any other neurotransmitters found in the cholinergic nerves. When compared to an untreated
site, the site with botulinum toxin did not have a significant increase in blood flow or sweat rate
(22). Because no vasodilation or sweating occurred with the presence of botulinum toxin, active
vasodilation is dependent on the release of a neurotransmitter from the cholinergic nerves.
One promising cotransmitter found in cholinergic nerve terminals is vasoactive intestinal
peptide (VIP). Using immunohistochemical staining, Lundberg et al. (28) found significant
amounts of VIP and ACh present in cholinergic nerves controlling exocrine glands in cats.
Bennett et al. (3) used intradermal microdialysis probes to infuse VIP and VIP (10-28) fragment,
a VIP antagonist, into human skin. 7.5 μM of VIP caused cutaneous dilation of similar
magnitude as seen during heating in humans. When VIP (10-28) was infused at levels of 214
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μM with and without atropine, a significant decrease in vasodilation occurred. During heating,
the site with VIP (10-28) alone caused blood flow to increase to around 27 % of maximum blood
flow. With VIP (10-28) and atropine, blood flow levels increased to around 20 % maximum
blood flow. The blood flow in the control site increased to 35 % of maximum blood flow (3).
The findings of Bennett provide evidence that VIP could play a role in active vasodilation in the
skin in humans.
Despite evidence of the importance of VIP in cutaneous vasodilation, other findings show
that VIP may not play an important role. Savage, Brengelmann, Buchan, and Freund (30)
studied subjects with cystic fibrosis. Using immunohistochemical analysis, they found that these
subjects had very little VIP present in their nerve endings. Despite a relative lack of VIP
released, subjects with cystic fibrosis had similar increases in blood flow when compared to
control subjects without cystic fibrosis (30). Even though VIP was almost absent in patients with
cystic fibrosis, vasodilation still occurred during heating. As such, other substances besides VIP
may also contribute to cutaneous vasodilation during thermal stress.
Nitrogen Oxide and Vasodilation
Besides the involvement of VIP and ACh in causing vasodilation, NO may also play an
important role. Nitric oxide is made from arginine by different nitric oxide synthase (NOS)
enzymes that are found in endothelial cells surrounding blood vessels or in cholinergic nerve
endings and sweat glands (7). The main NOS enzymes involved in skin blood flow regulation
are endothelial NOS (eNOS) (24) and neuronal NOS (nNOS) (25). One way that NOS is
activated is through shear stress on the blood vessels (8). Another way that NOS is activated is
from the release of ACh from nerve endings that bind to endothelial cells (6). Nitric oxide
synthase enzymes are also activated by action potentials that cause NOS to make NO from
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arginine and release NO from the nerve endings (6). Nitric oxide has a short half-life and
therefore influences cells close to its release site (13).
Because NO is located around blood vessels, it may be a key player in the control of skin
blood flow during heat stress. Researchers have reported an increase in intradermal NO
concentration during heat stress. Kellogg et al. (23) placed a NO-selective, amperometric
electrode in the forearm to measure concentrations of NO before and during heating. Significant
increases in blood flow and NO occurred during whole-body heating. When ACh was infused in
the skin, significant increases in skin blood flow and NO levels also occurred (23). The increase
in NO levels concomitantly with increasing temperature demonstrates that NO is involved in the
vasodilation and may actually be the substance that causes vasodilation.
One way to investigate NO’s role in reflexive control of blood flow is to block NO
synthase (NOS). Kellogg et al. (19) inserted intradermal microdialysis probes in the forearm of
subjects and perfused one site with nitro-L-arginine methyl ester (L-NAME) which is a
nonselective blocker of NOS, and the other site was perfused with Ringer solution. In the
untreated site when local skin temperature was raised to 38-38.5 °C, blood flow rose to 44 % of
maximum blood flow and in the L-NAME site blood flow rose to 30 % maximum blood flow
(19). By blocking NOS, blood flow did not increase similarly to blood flow in skin with
unblocked NOS. Nitric oxide production is clearly needed during local heating to induce
increases in skin blood flow.
Other studies using the NOS inhibitor NG-monomethyl-L-arginine (L-NMMA) report
similar results in attenuating blood flow. Shastry, Dietz, Halliwill, Reed, and Joyner (31) heated
subjects using a water-perfused suit and increased body core temperature by 1°C. NGmonomethyl-L-arginine was infused after heating into the blood through a brachial artery
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catheter at 5 mg/min for 21 minutes. Using laser Doppler flowmetry, they found that skin blood
flow levels decreased by 14 % during heating in the treated forearm when L-NMMA was
infused. This was significantly lower than the pre-L-NMMA values (31). The decreased levels
of blood flow following L-NMMA treatment demonstrate that NO is likely involved in active
cutaneous vasodilation. However, NOS inhibition did not completely decrease blood flow to
baseline levels. Either the dose of NOS inhibitor was insufficient to completely block NO
production or other substances must be involved in the process of vasodilation.
If NO is important for cutaneous vasodilation, then the question that arises is how does
ACh affect NO release, and do they need each other for vasodilation to occur or are they additive
to each other?

Shastry, Minson, Wilson, Dietz, and Joyner (32) investigated this question by

heating subjects in water-perfused suits to increase body core temperature by 1°C. After heating
subjects, 58 μM of atropine were infused for 30 minutes and then 10 mM of L-NAME was
infused for 30 minutes. During the infusion of atropine, subjects showed little change in skin
blood flow. However, during the administration of L-NAME, skin blood flow decreased
significantly compared to the control site which remained constant throughout the infusion.
They concluded from these results that ACh is not necessary to maintain vasodilation during
heating and that NO is probably not a by-product of ACh’s action on other tissues (32).
Shibasaki, Wilson, Cui, and Crandall (33) performed their infusions at the beginning of
heating instead of during full vasodilation. They tested if ACh from cholinergic nerves caused
vasodilation through NO at the beginning of heating. Three microdialysis sites were chosen on
the forearm. One site was a control site infused with Ringer solution while another site was
perfused with neostigmine, an acetylcholinesterase inhibitor, and the third site with neostigmine
and L-NAME. They found that during early heat stress vasodilation occurred significantly

48
sooner in the site with neostigmine. However, the site with neostigmine and L-NAME did not
vasodialate earlier. Throughout the experiment, blood flow in the L-NAME site was lower than
at other sites (33). The results of Shibasaki et al.’s experiment provide evidence that ACh
operates through a NO dependent mechanism in early stages of heating due to a decrease in the
onset of vasodilation when NO was blocked.
Recent evidence suggests that nNOS produces the NO that causes reflex vasodilation
seen during whole-body heating. Kellogg et al. (25) used 7-nitroindazole (7-IN) a selective
antagonist of nNOS to study nNOS involvement in thermoregulatory reflex vasodilation. One
site was infused with 5 % DMSO and Ringer solution, while the other site was infused with 2
mM 7-NI with 5 % DMSO. In one protocol subjects core temperature was elevated by 1°C
using a whole-body suit with the forearm being uncovered. In another protocol subject’s
forearms were locally heated to 41.5 °C. In the whole-body heating protocol, 7-NI significantly
decreased skin blood flow when compared to the control site by 15 %. However, in the protocol
with local skin warming, no significant difference was seen between the 7-NI site and control
site (25). Kellogg et al.’s findings clearly show that nNOS is involved in the thermoregulatory
reflex response during whole-body heating due to the attention seen with the blockade of nNOS.
More evidence supporting the involvement of nNOS in reflex response to whole-body
heating has been done by studying the combined effects of eNOS and nNOS blocking agents on
skin blood flow. Kellogg, Zhao, and Wu (26) infused the eNOS antagonist Nω-amino-L-arginine
(LNAA) and the nNOS antagonist Nω-propyl-L-arginine (NPLA) separately and in combination.
During whole-body heating, the site with NPLA had significantly attenuated skin blood flow, but
the site with NPLA and LNNA had no significant change from the NPLA site (26). The authors
concluded that because no difference in blood flow occurred when blocking both eNOS and
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nNOS compared to blocking with only nNOS during whole-body heating that nNOS is the main
contributor of NO during reflex thermoregulation.
Axon Reflex Control
Another way that the body controls skin blood flow is through a local axon reflex. This
system involves the sensory nociceptors in the skin which release neuropeptides, such as CGRP
and Substance P, which cause neurogenic vasodilation. Some researchers have used
transcutaneous electrical stimulation to study the effect of activating these nociceptors on skin
blood flow.
Early work with transcutaneous electrical stimulation was done to test nociceptor or pain
fiber functions in patients. Westerman et al. (38) tested the effects of electrical stimulation on
nociceptor nerves in the skin. Using an anode and a cathode electrode placed on top of the skin,
they applied 2, 4, 8, 16, and 32 electrical impulses to the skin at 2 Hz frequency with 150 volts at
0.5-1.0 ms duration per pulse

All subjects felt pain at the cathode site. Six subjects received a

capsaicin treatment to block the nociceptor fibers while the others did not receive a treatment.
Cutaneous skin blood flow was measured with a laser Doppler probe. With increasing number
of electrical impulses, an increase in blood flow was seen with and without capsaicin, but the
treatment with capsaicin was considerably less (38). Also, the level of perceived pain was less in
those who received the capsaicin treatment (38).
The stimulation was performed at a level where pain was perceived so that the
nociceptors were known to be active. Furthermore, the reduction in the magnitude of neurogenic
vasodilation with capsaicin treatment indicates that either the nociceptors were only partially
blocked or that other substances and/or nerve fibers were activated that contributed to the
dilation.
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Other studies have used surface electrical stimulation to stimulate neurogenic
vasodilation without invoking pain in subjects. Petrofsky, Hinds, Batt, Prowse, and Suh (29)
used rubber surface electrodes to stimulate activation of blood flow in the skin without invoking
pain. The electrodes were placed 4 cm apart on the quadriceps muscle. Skin blood flow
increased significantly during electrical stimulation. Between the electrodes, epinephrine and LNAME were delivered to the skin through iontophoresis and blood flow decreased significantly
prior to electrical stimulation but blood flow did not differ significantly during the electrical
stimulation (29). They concluded that the increase in blood flow seen during electrical
stimulation was caused mainly by NO because L-NAME treatment caused resting blood flow to
decrease and the increase in blood flow during electrical stimulation was abolished (29).
Conclusion
Despite our current knowledge of how skin blood flow is controlled, there are still
numerous questions about the exact mechanism and the interaction of the various control
systems in regulating skin blood flow. Heating and cooling the body activate thermosensitive
neurons that change blood flow. The sympathetic nervous system (SNS) causes vasoconstriction
during cold stress through the action of sympathetic adrenergic nerves. The SNS also causes
vasodilation through the action of a sympathetic cholinergic dilator nerve (unknown
neurotransmitter or cotransmitter). The different neurochemicals from the cholinergic nerves
that may cause this vasodilation are ACh and VIP. However, conflicting evidence remains on
the importance of each one, and how they are involved with each other.
Beside the involvement of the SNS in reflex skin blood flow, NO is an important local
factor in controlling skin blood flow. The presence of NO causes vasodilation and may be a part
of the pathway that ACh uses to increase skin blood flow. Finally, an axon reflex can be
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initiated when nociceptors are activated. These activated nociceptors release CGRP which
increase skin blood flow. The axon reflex has been simulated through the use of surface
electrical stimulation however it is unclear if this reflex response is activated during skin
warming. More research needs to be done in an in-vivo setting to help gain a greater knowledge
of how these regulatory pathways interact to control skin blood flow. Skin blood flow is a vital
component in maintaining livable body temperature during exercise and temperature changes.
Other diseases such as Raynaud’s disease and diabetes where cutaneous circulation are impaired
could significantly benefit from a greater understanding of the factors controlling cutaneous
circulation.
In this proposal we describe a novel approach to understanding the control of skin blood
flow by perivascular nerves. In this model we will use graded intradermal electrical stimulation
to depolarize perivascular nerves and monitor the local skin blood flow response. By
simultaneously applying a variety of receptor antagonists via intradermal microdialysis, we hope
to eliminate the actions of many known chemical modulators of skin blood flow and quantify
their contribution to either vasoconstrictor or vasodilator responses.
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Chapter 3
Methods

Experimental Design
A randomized control trial will be used to examine the influence of acetylcholine (ACh),
nitric oxide (NO), and vasoactive intestinal peptide (VIP) released from the sympathetic
perivascular nerves during electrical field stimulation on skin blood flow. Treatments will be
randomly assigned to different sites on the dorsal aspect of the forearm of each subject.
Subjects
Fifteen male or female subjects 18-35 years old will be recruited to participate in the
study. Subjects will be recruited from classes at Brigham Young University. Subjects will
apparently be healthy and not taking any medications. Subjects with a history of renal or
cardiovascular disease will be excluded from the study. All subjects will complete a health
questionnaire to determine if they meet the inclusion criteria. Female subjects will be tested
during the first seven days of their menstrual cycle to avoid fluctuations in sex hormones.
Subjects will be asked to avoid consumption of alcohol and caffeine and avoid exercise 12 hours
prior to participation in the study. The study will be approved by the Brigham Young University
Institutional Review Board prior to data collection. All subjects will provide written informed
consent prior to participation. Subjects will be told they can quit at any time with no
consequence.
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Environmental Conditions
Each subject will be fitted with a water-perfused suit that covers the entire body except
the head, feet, hands, and left forearm that is being tested. The water perfusing through the suit
will be set at 34 °C throughout the experiment. The upper and lower parts of the water-perfused
suit will be connected with interlocking tubing and connected to a manifold that allows switching
the inlet water from either a cold or warm water bath. The warm water bath will be set to 34 °C
and the cold water bath will be set at 4 °C. The suit will be perfused with warm water
throughout the experiment except when testing for reflex constriction of the skin blood vessels
which will be produced by switching the suit to the cold water bath for three minutes. The room
temperature will be set to 28 + 0.5 °C throughout the experiment.
Subject Preparation
Subjects will be seated upright in a dental chair throughout the procedure. Three probe
sites will be chosen on the dorsal side of the left forearm 3-4 cm from the elbow. Each site will
be approximately 4-5 cm away from each other. Scissors will be used to cut arm hair close to the
skin at each site to minimize skin irritation. Iodine and alcohol will be applied to the skin to
sterilize insertion and exit sites of the microdialysis probes.
After the skin is prepared, intradermal microdialysis probes will be inserted across the
forearm into each site. Microdialysis probes will be constructed in the biochemistry lab
(Appendix A). A 27 gauge needle will be inserted underneath the skin at a depth of 1-2 mm for
a length of 3 cm and then exit out of the skin. A microdialysis probe will be threaded through
the needle, and the needle will be removed. The hollow fiber of the tube will be adjusted so that
it is directly under the skin. All three sites will be perfused at 10 µl/min with a sterile, 0.9 %
saline solution for the first 15 minutes of the experiment.
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Specially made laser Doppler probe holders will be placed on the skin directly over the
path of the hollow fiber portion of the microdialysis probe using double-stick tape. The laser
Doppler probe holder has one hole directly in the center where a laser Doppler flow probe will
be placed. The laser Doppler probe (Moor Instruments, Devon, England) will be used to
measure skin blood flow. On either side of the laser Doppler probe hole are two guide tubes
where electrical stimulating electrodes (stainless steel acupuncture needles) will be inserted 2
mm deep into the skin. The tips of the stimulating electrodes will be 4-5 mm apart. The guide
tube prevents the stimulating electrodes from penetrating the skin more than 2 mm. The
stimulating electrodes are connected to a constant current stimulator (Model DS7AH, Digitimer
Ltd., West Garden City, England). Local skin temperature will be measured using a
thermocouple wire placed between the probe holder and the skin.
Heart rate and blood pressure will be measured using an automated blood pressure
machine (Model STBP-780, Colin Medical Instruments, Komaki, Japan). The blood pressure
cuff will be put on the upper right arm of subjects one inch above the antecubital space and
underneath the water-perfused suit. Two electrodes used to measure heart rate will be placed at
the midclavicular point below the clavicle on the left and right side of the chest. The other
electrodes will be placed in fifth intercostal space at the midclavicular line on the left side of the
torso. Blood pressure will be measured five minutes before the cold pressure test and every
minute during the cold pressor test. Also, heart rate and blood pressure will be measured five
minutes before electrical field stimulation and every minute during electrical field stimulation.
Determination of Stimulus Amplitude
The experiment will invoke an electrical stimulus that activates the perivascular nerves
surrounding the cutaneous blood vessels. The typical response of electrical stimulation on the
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perivascular nerves over a period of 60 seconds is a decrease in skin blood flow (Figure 1). The
magnitude of the electrical stimulus is determined for each subject using the following
procedure. A Grass stimulator (Model Grass S88 Stimulator, Grass Instrument Co., Quincy,
MA) controlling the frequency and a digitimer constant current stimulator (Model DS7AH,
Digitimer Ltd., West Garden City, England) controlling the amplitude will initially be set at a
frequency of 8 Hz and an amplitude of 0.5 mA, respectively. The stimulus should feel like a
“tapping” sensation on the skin. If the subject does not feel the stimulus at 0.5 mA, then the
amplitude will be increased 0.1 mA every five seconds until the stimulus is detected. If the
stimulus is felt at 0.5 mA, the amplitude will be decreased 0.1 mA every five seconds until the
stimulus is not detected. The amplitude 0.1 mA above where the stimulus was not detected will
be used.
At the determined initial amplitude and at a frequency of 8 Hz, the electrical stimulus will
be turned on, and the current will be increased 0.2 mA every 20 seconds until a significant
increase or decrease in skin blood flow occurs. A significant change will occur when skin blood
flow readings measured by laser Doppler probes (Moor Instruments, Devon, England) change
from baseline levels by 0.5-0.7 V as recorded on the computer program chart. Once a significant
increase or decrease in skin blood flow is seen, the stimulus will be stopped. Five minutes later
the selected amplitude will be retested for one minute at a frequency of 8 Hz to make sure that a
significant change occurs. If a significant change of 0.5-0.7 V happens, then this amplitude will
be used as the determined experimental amplitude. If no significant response is seen, then the
amplitude will be increased 0.2 mA and retested five minutes later for one minute. The
amplitude will be increased in this manner until a significant change results.
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Subjects will be asked to rate the pain experienced by the electrical field stimulation
using a 120 mm visual analog scale with anchors at 0 (no pain) and 100 mm (unbearable pain).
Staircase Stimulus Protocol
A dose response curve invoking increasing stimulus frequencies will be performed at
each treatment site and skin blood flow will be measured. The predetermined stimulating current
will remain the same throughout the rest of the experiment. The frequency will be changed in a
staircase manner from 0.2 to 32 Hz. The starting frequency of 0.2 Hz will last one minute and
then the frequency will increase to 1 Hz which will last one minute. This pattern will continue
with 2 Hz, 4 Hz, 8 Hz, 16 Hz, and 32 Hz. The total time to go through the five different
frequencies will be seven minutes. For each stimulus frequency the skin blood flow response
will be characterized by the area under the skin blood flow–time response curve (AUC) for one
minute where skin blood flow is expressed as a percent of resting blood flow prior to electrical
stimulation. The dose response curve therefore reflects the plot of stimulus frequency versus the
AUC for skin blood flow.
Evidence Supporting Staircase Stimulus Protocol
During preliminary testing, five subjects were tested using the staircase method, and five
subjects were tested by randomly assigning different frequencies and waiting five minutes
between each stimulus. The frequencies tested ranged from 0.2-32 Hz. The average response of
each method was similar for both the staircase and randomized frequency protocols (Figure 2).
Both protocols produced similar results so the staircase frequency protocol will be used because
of its shorter time period.
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Bretylium Tosylate Blockade of Sympathetic Noradrenergic System
100 mM bretylium tosylate (Appendix B) will be delivered to the skin during a 90 minute
perfusion period. Bretylium is taken up by the adrenergic neurons and blocks the release of
norepinephrine from the axons. When this system is blocked vasoconstriction of the cutaneous
blood vessels will not be invoked when the cutaneous sympathetic nerves are activated during a
whole-body cold challenge. The absence of a cold induced cutaneous vasoconstriction will be
used to verify adequate delivery of bretylium tosylate to the skin. In addition, preliminary
studies indicate that electrical field stimulation of cutaneous perivascular nerves typically
produces the activation of sympathetic adrenergic nerves and vasoconstriction. This effect is
typically prevented by application of bretylium tosylate, again verifying the blockage of
sympathetic noradrenergic nerves (Figure 3). Bretylium tosylate is in short supply at the
moment. In the case that bretylium tosylate is not available, phentolamine and propranolol will
be used to block alpha and beta-adrenergic receptors and BIBB-3622 to block neuropeptide Y
(34).
Bretylium Infusion
Bretylium will be infused at 5 µl/min with a Harvard infusion pump (Model PHD 2000,
Harvard Apparatus, Holliston, MA) for 120 minutes in all three sites and be considered the
control condition. After 120 minutes, the electrical field stimulation will be done on all three
sites and skin blood flow response will be recorded. Bretylium’s effects last 4-5 hrs. A post trial
cold pressor test will be used to verify blockade.
ACh Blockade
0.1 mg/ml atropine sulfate (Appendix B), an antagonist of ACh receptors, will be
delivered to two of the three skin sites. Infusion of atropine will block the action of ACh during
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electrical stimulation on ACh receptors in the cutaneous vasculature. Atropine will be infused
for 30 minutes at 5 µl/min. The electrical field stimulation staircase protocol will be used to
examine atropine’s effect on skin blood flow.
ACh and NO Blockade
In one of the sites where ACh was blocked, a solution of 0.1 mg/ml atropine and 10 mM
nitro-L-arginine methyl ester (L-NAME) (Appendix B) will be infused for 30 minutes at a rate of
5 µl/min. Nitro-L-arginine methyl ester is a nonselective antagonist of NO synthase and will be
used to prevent NO production. After infusion, the electrical field stimulation staircase protocol
will be done.
ACh, NO, and VIP Blockade
In the other site where ACh was also previously blocked, 200 µM of the VIP receptor
antagonist (p-Chloro_D-Phe6,Leu17)-VIP or (10-28)-VIP, 10 mM L-NAME, and 0.1 mg/ml
atropine will be infused in the site (Appendix B). The drug infusion will last 30 minutes and be
infused at a rate of 5 µl/min. The electrical field stimulation staircase protocol will be done at
the end of infusion.
Maximum Blood Flow
Following the final stimulation period, maximum skin blood flow will be determined by
application of 28 mM sodium nitroprusside (SNP) (Appendix B). All drugs will be delivered by
intradermal microdialysis at a rate of 5-10 µl/min with a Harvard infusion pump (Model PHD
2000, Harvard Apparatus, Holliston, MA) for 30-45 minutes.
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Outline of Specific Protocol
Subjects will have an orientation meeting for 15-30 minutes where the experiment will be
explained and a health questionnaire and consent formed will be filled out. At the next meeting,
subject’s height, weight and age will be recorded. Subjects will have avoided eating any
caffeine, drinking any alcohol or exercising 12 hours prior.
Microdialysis probes will be inserted and probe holders, laser Doppler probes, and
stimulating electrodes will be set up. Approximate set-up time is 30 minutes. Sterile saline
solution will be pumped at a rate of 10 µl/min for 15 minutes. At the end of 15 minutes, a cold
pressor test will be done for three minutes. After that the experimental current amplitude for
each site will be determined for 10-30 minutes. Bretylium tosylate will then be infused for 90
minutes, and then a cold pressor test will be done for three minutes. After the cold pressor test,
bretylium will continue to be infused for 30 minutes.
After 120 minutes of bretylium infusion in all three sites, the first electrical staircase
stimulation will be performed. Five minutes after stimulation atropine will be infused in the two
of the three sites. After 30 minutes of infusion, another staircase stimulation will be done in all
three sites. Five minutes after stimulation, atropine and L-NAME will be infused in one site and
atropine, L-NAME, and VIP will be infused in another site. After infusion for 30 minutes, a
staircase will be performed in all three sites. Five minutes after the staircase stimulus a cold
pressor test will be done to confirm blockade of sympathetic noradrenergic neurons. Five
minutes later SNP will be infused for 30-45 minutes at all skin sites to obtain maximum skin
blood flow levels (Figure 4).
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Data Acquisition
All data from laser Doppler probes, thermocouples, and electrical stimulus will be
recorded with Powerlab - 16 channel A/D converter (Powerlab/16 SP, ADInstruments Pty Ltd.,
Castel Hill, Australia) at 400 Hz using the computer program chart.
Data Analysis
Comparisons between treatments will be done using repeated measures analysis of
variance (ANOVA). Statistical significance will occur when p values are less than 0.05.
Specific comparisons between treatment sites will be performed using the Tukey minimum
significant difference post-hoc test. Major variables to be measured are local skin temperature
(°C), skin blood flow (v), heart rate (bpm), blood pressure (mmHg), and perceived pain levels.
Skin blood flow will be converted to cutaneous vascular conductance (CVC) by taking SkBF
(V)/ Mean Arterial Pressure (mm HG)*100. Cutaneous vascular conductance will be expressed
as a percent of maximum CVC. Changes from baseline will be calculated by taking the baseline
average one minute before stimulus minus the value during electrical field stimulation. Area
under the curve will be calculated from the sum of the second-by-second differences from
baseline for each stimulus frequency.
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Figure 1. Skin blood flow response to 60 seconds of electrical stimulation. AUC = area under the skin
blood flow–time response curve where skin blood flow is expressed as a percent of resting blood flow
prior to electrical stimulation. The dose response curve therefore reflects the plot of stimulus frequency
versus the AUC for skin blood flow.
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Figure 2. Dose Response Curve. AUC = area under the skin blood flow–time response curve
where skin blood flow is expressed as a percent of resting blood flow prior to electrical
stimulation. The dose response curve therefore reflects the plot of stimulus frequency versus the
AUC for skin blood flow. Both randomized and staircase procedures produced similar responses
at the same frequencies.
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Figure 3. Bretylium effects on skin blood flow. AUC = area under the skin blood flow–time
response curve where skin blood flow is expressed as a percent of resting blood flow prior to
electrical stimulation. The dose response curve therefore reflects the plot of stimulus frequency
versus the AUC for skin blood flow. Skin blood flow response to electrical stimulation with
saline and with 100 mM Bretylium Tosylate. Bretylium effectively inhibits the sympathetic
noradrenergic system causing only the sympathetic dilator system to be active.
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Figure 4. Experiment timeline. B stands for bretylium, SNP stands for sodium nitroprusside,
EFS stands for electrical field stimulation, CPT stands for cold pressor test, VIP (10-28) stands
for Vasoactive intestinal peptide antagonist, and L-NAME stands for nitro-L-arginine methyl
ester. Estimated total time is 4 hours 45 minutes.
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Appendix A -- Construction and insertion of microdialysis probes
Microdialysis Probe Materials
Two microdialysis probes will be inserted into the dorsal side of the forearm of the
subjects approximately 3-5 cm from the elbow. Microdialysis probes are constructed in the
biochemistry lab. A 45 cm stainless steel wire (Alan Baird Ind., Ho-Ho-Kus, NJ) composes the
skeleton of the microdialysis probe. A 25 gauge luer stub adapter was attached to 4 cm long
polyethylene (PE) 50 tubing. Six cm of PE 10 tubing was inserted 2 cm into the PE 50 tubing.
Inserted into the PE 10 tubing approximately 2 cm was the 22 cm long polyimide tubing (A-M
Systems, Inc). The 4.5 cm long hollow fiber dialysis membrane (Spectra-Por regenerated
cellulose microdialysis hollow fibers) went one inch over the polyimide tubing. At the opposite
end of the 4.5 cm hollow fiber, polyimide tubing was inserted into the hollow fiber one inch.
Two and a half cm of hollow fiber was unobstructed to allow chemicals to diffuse freely through
the hollow membrane.
Insertion of Microdialysis Probes
1. Skin preparation for insertion of the microdialysis probes consists of marking a 3 cm
distance on the dorsal forearm where the microdialysis hollow fiber will go under the
skin.
2. An alcohol pad will clean the two sides of the 3 cm line where a 27 gauge needle will be
inserted and will leave the skin.
3. After letting the alcohol dry for a few seconds, a cotton swab will be dipped in iodine and
then rubbed in a circular motion on the two ends of the line where the alcohol swab was
used. Do this two times. Let it dry on the skin. Skin is now ready for needle insertion.
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4. Open a sterile pad and place it on a flat surface in preparation to put the microdialysis
probe and needle on it.
5. Carefully open the microdialysis probe package being sure not to touch the part of the
probe that enters the skin.
6. Using a syringe with saline, check to make sure that the microdialysis probe has no leaks.
You can touch the stub adapter and insert the syringe. Slowly infuse saline through the
microdialysis probe and look at the joints of the probe to make sure saline is not leaking.
7. Fix joints as needed or get a new microdialysis probe.
8. Place microdialysis probe on sterile pad.
9. Open 27 gauge needle package and place on sterile pad without touching needle.
10. Put on sterile gloves. Only touch the inside with hands. Outside of gloves only to be
touched with the gloves themselves.
11. Insert needle from medial side of marked line so that it leaves the lateral side of arm.
Take the needle and while pulling down skin to make the skin tight insert the needle into
the skin.
12. Do not go too deep into the skin but 1-2 mm below the skin surface. You should see a
slight protuberance that indicates where the needle is.
13. Poke needle through skin when you get to the end of the 3 cm line.
14. Insert microdialysis probe into the needle until the end of the hollow fibers gets to the end
of the needle.
15. Pull needle through skin.
16. Adjust microdialysis probe to where the hollow fiber is underneath the skin between the
ends of the marked line.
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17. Place a piece of tap where the microdialysis probe enters and leaves the skin so it does
not move.
18. Mark on the tape with a straight line where the microdialysis probe enters and leaves
skin.
19. Infuse saline through sites until electrical stimulation amplitude is determined.
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Appendix B -- Preparation of drugs
Bretylium Tosylate
a. MW = 414.4 g/mole.
b. Make a 100 mM solution of Bretylium Tosylate.
c. 100 mM = 0.1 M = 0.1 moles/L.
d. Amount needed: 0.1 moles/L x 414.4 g/mole = 41.44 g/L = 41.44 mg/ml.
e. Weigh out Bretylium close to 41.44 mg in a sterile eppendorph tube.
f. Record weight of Bretylium.
g. Take measured (mg)/41.44 mg/ml to determine how much saline is needed for the
solution.
h. Put sterile saline in eppendorph with Bretylium.
i. Mix well (vortex).
j. Draw solution in a syringe and then push solution through a um sterile filter into
another syringe.
k. Label syringe and place in package.
l. Make 3 syringes with Bretylium Tosylate.
Atropine Dose = 0.1 mg/ml
a. Make a 0.1 mg/ml atropine solution.
b. MStock = 0.4 mg/ml.
c. VStock = ?.
d. Mdilution = 0.1 mg/ml.
e. Vdilution = 1 ml.
f. Mdilution Vdilution = MStock VStock.
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g. 0.1 mg/ml x 1 ml = 0.4 mg/ml x ?.
h. VStock = (.01 mg/ml x 1 ml)/ 0.4 mg/ml = 0.25 mL.
i. Combine 0.25 mL of stock with 0.75 mL saline.
L-NAME
a. MW = 269.69 g/mole.
b. Make a 10 mM solution.
c. 10 mM = .01 M = .01 moles/L.
d. Amount needed: 269.69 g/mole x .01 mole/L = 2.6969 g/L = 2.6969 mg/ml.
e. Weigh out L-NAME close to 2.6969 mg in sterile eppendorph tube.
f. Record weight of L-NAME.
g. Take measured (mg)/2.6969 mg/ml to determine how much saline is needed for
the solution.
h. Put saline in eppendorph tube with L-NAME.
i. Put solution in a syringe and then put it through a cold filter into another syringe
to sterilize solution.
j. Put syringe in package and label.
Sodium Nitroprusside (SNP)
a. MW = 297.95 g/mole.
b. Make 28 mM solution.
c. 25 mg/ml solution.
d. What is 25 mg/ml concentration (mM)?.
e. 25 mg/ml x 1 g/1000 mg x 1 mol/295.95 g x 1000 mmoles/1 mole x 1000 mL/1 L
= 84.47 mM.
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f. MStock = 84.47 mM.
g. VStock = ?.
h. Mdilution = 28 mM.
i. Vdilution = 0.5 mL.
j. Mdilution Vdilution = MStock VStock.
k. 28 mM x .5 mL = 84.47 mM x ?.
l. VStock = (28 mM x .5 mL)/84.47 mM = .17 mL.
m. Combine .17 mL of stock with .33 mL saline.
Saline
a. Clean top of saline bottle with alcohol pad.
b. Insert needle in top and fill syringe.
c. Fill three syringes with saline.
VIP receptor antagonist- 200 μM (p-Chloro_D-Phe6,Leu17)-VIP.
Antagonists needed if Bretylium Tosylate is not available (34).
NPY antagonist- 10.5 μM BIBP-3226.
Beta-adrenergic antagonist
1 mM Propranolol.
Alpha-adrenergic antagonist
0.5 mM Phentolamine - Nonselective alpha-adrenergic receptor antagonist
or
5 mM Yohimbine – Selective Alpha-1-adrenergic receptor antagonist
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